| Prelude Fertility | 68.9 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 68.9 | 3 | 1 |
| Mayo Clinic | 60.0 | 4 | 0 |
| Human Rights Campaign | 60.0 | 4 | 0 |
| Frontiers in Energy Efficiency | 60.0 | 4 | 0 |
| Colorado Center for Reproductive Medicine | 58.2 | 2 | 1 |
| Sher Fertility | 58.2 | 2 | 1 |
| Pacific Fertility Center | 51.7 | 3 | 0 |
| Challenges and strategies in building a foundational digital health data integration ecosystem: a systematic review and thematic synthesis | 51.7 | 3 | 0 |
| Clinical trial NCT07597382 | 51.7 | 3 | 0 |
| Clinical trial NCT07585825 | 51.7 | 3 | 0 |
| Clinical trial NCT07571616 | 51.7 | 3 | 0 |
| Clinical trial NCT07571629 | 51.7 | 3 | 0 |
| Clinical trial NCT07611032 | 51.7 | 3 | 0 |
| American Society for Reproductive Medicine | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New York | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New Jersey | 43.1 | 1 | 1 |
| Massachusetts General Hospital | 41.0 | 2 | 0 |
| Nucleic Acids Research | 41.0 | 2 | 0 |
| Q229883 | 41.0 | 2 | 0 |
| National Cancer Institute | 41.0 | 2 | 0 |
| Ferring Pharmaceuticals | 41.0 | 2 | 0 |
| The University of Texas MD Anderson Cancer Center | 41.0 | 2 | 0 |
| Frontiers in Neuroanatomy | 41.0 | 2 | 0 |
| Frontiers in Cellular Neuroscience | 41.0 | 2 | 0 |
| Frontiers in Pharmacology | 41.0 | 2 | 0 |
| Frontiers in Psychology | 41.0 | 2 | 0 |
| Rusk Institute of Rehabilitation Medicine | 41.0 | 2 | 0 |
| Cleveland Clinic | 41.0 | 2 | 0 |
| American Family Physician | 41.0 | 2 | 0 |
| American Journal of Translational Research | 41.0 | 2 | 0 |
| Biomedical Optics Express | 41.0 | 2 | 0 |
| Carilion Clinic | 41.0 | 2 | 0 |
| ClinicalTrials.gov | 41.0 | 2 | 0 |
| dbSNP | 41.0 | 2 | 0 |
| Henry Ford Health | 41.0 | 2 | 0 |
| H. Lee Moffitt Cancer Center & Research Institute | 41.0 | 2 | 0 |
| Northwell Health | 41.0 | 2 | 0 |
| Western Journal of Medicine | 41.0 | 2 | 0 |
| Trends in Amplification | 41.0 | 2 | 0 |
| Ulster Medical Journal | 41.0 | 2 | 0 |
| The AAPS Journal | 41.0 | 2 | 0 |
| Rice | 41.0 | 2 | 0 |
| AAPS PharmSciTech | 41.0 | 2 | 0 |
| International Journal of Mental Health Systems | 41.0 | 2 | 0 |
| Journal of Urban Health | 41.0 | 2 | 0 |
| Neural Development | 41.0 | 2 | 0 |
| Journal of the Society of Laparoendoscopic Surgeons | 41.0 | 2 | 0 |
| Frontiers in Systems Neuroscience | 41.0 | 2 | 0 |
| Frontiers in Energy Research | 41.0 | 2 | 0 |
| UCLA Health System | 41.0 | 2 | 0 |
| Q20641742 | 41.0 | 2 | 0 |
| NewYork-Presbyterian Westchester | 41.0 | 2 | 0 |
| Frontiers in Bioengineering and Biotechnology | 41.0 | 2 | 0 |
| Oregon Graduate Center | 41.0 | 2 | 0 |
| The Journal of clinical and aesthetic dermatology | 41.0 | 2 | 0 |
| Alcohol research : current reviews | 41.0 | 2 | 0 |
| American Society of Clinical Oncology educational book / ASCO | 41.0 | 2 | 0 |
| Dermato-endocrinology | 41.0 | 2 | 0 |
| British Heart Journal | 41.0 | 2 | 0 |
| The western journal of emergency medicine | 41.0 | 2 | 0 |
| Psychiatry | 41.0 | 2 | 0 |
| Mycobiology | 41.0 | 2 | 0 |
| Frontiers in Psychiatry | 41.0 | 2 | 0 |
| Frontiers in Endocrinology | 41.0 | 2 | 0 |
| Frontiers in Plant Science | 41.0 | 2 | 0 |
| Frontiers in Cell and Developmental Biology | 41.0 | 2 | 0 |
| Frontiers in Ecology and Evolution | 41.0 | 2 | 0 |
| Frontiers in physics | 41.0 | 2 | 0 |
| San Diego Fertility Center | 41.0 | 2 | 0 |
| Carilion Roanoke Community Hospital | 41.0 | 2 | 0 |
| Shady Grove Fertility Center | 41.0 | 2 | 0 |
| Fertility Centers of Illinois | 41.0 | 2 | 0 |
| New Hope Fertility Center | 41.0 | 2 | 0 |
| Syosset Hospital | 41.0 | 2 | 0 |
| Johns Hopkins Medicine | 41.0 | 2 | 0 |
| Advanced Optical Technologies | 41.0 | 2 | 0 |
| University of Utah Health Care | 41.0 | 2 | 0 |
| Oncology Issues | 41.0 | 2 | 0 |
| Christopher R. Conley | 41.0 | 2 | 0 |
| Frontiers in Genome Editing | 41.0 | 2 | 0 |
| Frontiers in Neurogenesis | 41.0 | 2 | 0 |
| Frontiers in Conservation Science | 41.0 | 2 | 0 |
| University of Pennsylvania Division of Endocrinology, Diabetes and Metabolism | 41.0 | 2 | 0 |
| Stanford Children's Health | 41.0 | 2 | 0 |
| Frontiers in Bioinformatics | 41.0 | 2 | 0 |
| Frontiers in Health Services | 41.0 | 2 | 0 |
| Progyny, Inc. | 41.0 | 2 | 0 |
| Frontiers in High Performance Computing | 41.0 | 2 | 0 |
| Frontiers in Sustainable Resource Management | 41.0 | 2 | 0 |
| Frontiers in Arachnid Science | 41.0 | 2 | 0 |
| Frontiers in RNA Research | 41.0 | 2 | 0 |
| Frontiers in Fish Science | 41.0 | 2 | 0 |
| Frontiers in Malaria | 41.0 | 2 | 0 |
| Frontiers in Bacteriology | 41.0 | 2 | 0 |
| Frontiers in Organizational Psychology | 41.0 | 2 | 0 |
| Frontiers in Epigenetics and Epigenomics | 41.0 | 2 | 0 |
| Frontiers in Medical Engineering | 41.0 | 2 | 0 |
| Frontiers in Mammal Science | 41.0 | 2 | 0 |
| Frontiers in Sustainable Energy Policy | 41.0 | 2 | 0 |
| Frontiers in Network Physiology | 41.0 | 2 | 0 |
| Ovarian tissue and oocyte cryopreservation | 40.0 | 0 | 4 |
| Ovarian tissue and oocyte cryopreservation | 40.0 | 0 | 4 |
| assisted reproductive technology | 34.5 | 0 | 3 |
| fertility clinic | 34.5 | 0 | 3 |
| Fertility and Sterility | 34.5 | 0 | 3 |
| Ovarian tissue and oocyte cryopreservation | 34.5 | 0 | 3 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 34.5 | 0 | 3 |
| Fertility-Preserving Treatment Options in Patients with Malignant Hematological Diseases | 34.5 | 0 | 3 |
| Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction: a committee opinion | 34.5 | 0 | 3 |
| Xenotransplantation of cryopreserved human ovarian tissue—a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment | 34.5 | 0 | 3 |
| Fertility Preservation Options for Men and Women With Cancer | 34.5 | 0 | 3 |
| Mature oocyte cryopreservation: a guideline | 34.5 | 0 | 3 |
| Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction | 34.5 | 0 | 3 |
| Prevalence and Predictors of Sperm Banking in Adolescents Newly Diagnosed With Cancer: Examination of Adolescent, Parent, and Provider Factors Influencing Fertility Preservation Outcomes | 34.5 | 0 | 3 |
| Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology? | 34.5 | 0 | 3 |
| Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years | 34.5 | 0 | 3 |
| What is the quality of information on social oocyte cryopreservation provided by websites of Society for Assisted Reproductive Technology member fertility clinics? | 34.5 | 0 | 3 |
| Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion | 34.5 | 0 | 3 |
| Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives†‡ | 34.5 | 0 | 3 |
| Re: Fertility Preservation for Men with Testicular Cancer: Is Sperm Cryopreservation Cost Effective in the Era of Assisted Reproductive Technology? | 34.5 | 0 | 3 |
| Egg Freezing Pilot Study | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 34.5 | 0 | 3 |
| Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 34.5 | 0 | 3 |
| Female fertility preservation: feasibility of emergency IVF for embryo freezing | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion | 34.5 | 0 | 3 |
| Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center | 34.5 | 0 | 3 |
| 6. Ovarian Tissue Cryopreservation Is a Feasible and Safe Procedure in a Pediatric, Adolescent and Young Adult Population for Fertility Preservation Prior to Gonadotoxic Treatment | 34.5 | 0 | 3 |
| GYN-FIV a.s. | 34.5 | 0 | 3 |
| Vitrification (ovocytes) | 27.3 | 0 | 2 |
| Journal of Assisted Reproduction and Genetics | 27.3 | 0 | 2 |
| Reproductive Medicine and Biology | 27.3 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 27.3 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 27.3 | 0 | 2 |
| Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation | 27.3 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 27.3 | 0 | 2 |
| Fertility preservation during cancer treatment: clinical guidelines | 27.3 | 0 | 2 |
| Surgical Aspects of Ovarian Tissue Removal and Ovarian Tissue Transplantation for Fertility Preservation | 27.3 | 0 | 2 |
| Ovarian tissue transport to expand access to fertility preservation: from animals to clinical practice | 27.3 | 0 | 2 |
| Impact of men's dairy intake on assisted reproductive technology outcomes among couples attending a fertility clinic | 27.3 | 0 | 2 |
| Fertility Preservation after a Cancer Diagnosis: A Systematic Review of Adolescents', Parents', and Providers' Perspectives, Experiences, and Preferences | 27.3 | 0 | 2 |
| Risk of major congenital anomalies after assisted hatching: analysis of three-year data from the national assisted reproduction registry in Japan | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A committee opinion | 27.3 | 0 | 2 |
| Pregnancy outcomes after assisted reproductive technology | 27.3 | 0 | 2 |
| The status of assisted reproductive technology in Korea in 2012 | 27.3 | 0 | 2 |
| Commentary. Cancer diagnosis - the role of urgent referral guidelines | 27.3 | 0 | 2 |
| Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007 | 27.3 | 0 | 2 |
| Fertility preservation among the cancer patients by ovarian tissue cryopreservation, transplantation, and follicular development | 27.3 | 0 | 2 |
| How the FMR1 gene became relevant to female fertility and reproductive medicine | 27.3 | 0 | 2 |
| Fertility preservation outcomes may differ by cancer diagnosis | 27.3 | 0 | 2 |
| Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation | 27.3 | 0 | 2 |
| Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes | 27.3 | 0 | 2 |
| Oocyte cryopreservation and ovarian tissue banking | 27.3 | 0 | 2 |
| Breast cancer in young women: special considerations in multidisciplinary care | 27.3 | 0 | 2 |
| Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner | 27.3 | 0 | 2 |
| Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. | 27.3 | 0 | 2 |
| Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment | 27.3 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due to Accelerated Follicle Loss in Turner Syndrome or Cancer Treatments | 27.3 | 0 | 2 |
| Fertility Preservation in Reproductive Age Women with Cancer | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion | 27.3 | 0 | 2 |
| Risk of breast cancer following fertility treatment—A registry based cohort study of parous women in Norway | 27.3 | 0 | 2 |
| Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients | 27.3 | 0 | 2 |
| A healthy delivery of twins by assisted reproduction followed by preimplantation genetic screening in a woman with X-linked dominant incontinentia pigmenti | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| Effect of Antifreeze Protein on Mouse Ovarian Tissue Cryopreservation and Transplantation | 27.3 | 0 | 2 |
| Semen Analysis in Cancer Patients Referred for Sperm Cryopreservation before Chemotherapy over a 15-Year Period in Korea | 27.3 | 0 | 2 |
| Cryopreservation time does not decrease follicular viability in ovarian tissue frozen for fertility preservation | 27.3 | 0 | 2 |
| Combined strategy for fertility preservation in an oncologic patient: vitrification of in vitro matured oocytes and ovarian tissue freezing | 27.3 | 0 | 2 |
| Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation | 27.3 | 0 | 2 |
| Optimal timing for elective egg freezing | 27.3 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction?: challenges in measuring and reporting success rates for assisted reproductive technology treatments: what is optimal? | 27.3 | 0 | 2 |
| Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? | 27.3 | 0 | 2 |
| Oncologists' use of patient educational materials about cancer and fertility preservation | 27.3 | 0 | 2 |
| Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment | 27.3 | 0 | 2 |
| Oocyte versus embryo cryopreservation for fertility preservation in cancer patients: guaranteeing a women's autonomy | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation for fertility preservation in cancer patients: successful establishment and feasibility of a multidisciplinary collaboration | 27.3 | 0 | 2 |
| The beneficial effects of polyethylene glycol-superoxide dismutase on ovarian tissue culture and transplantation | 27.3 | 0 | 2 |
| Oncofertility: a grand collaboration between reproductive medicine and oncology | 27.3 | 0 | 2 |
| Reasons Why Young Women Accept or Decline Fertility Preservation After Cancer Diagnosis | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI). | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| The role of fertility preservation in patients with endometriosis | 27.3 | 0 | 2 |
| Cancer and fertility preservation: fertility preservation in breast cancer patients | 27.3 | 0 | 2 |
| Implications of sperm banking for health-related quality of life up to 1 year after cancer diagnosis | 27.3 | 0 | 2 |
| Current status of assisted reproductive technology in Korea, 2011 | 27.3 | 0 | 2 |
| Cryopreservation/transplantation of ovarian tissue and in vitro maturation of follicles and oocytes: challenges for fertility preservation | 27.3 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 27.3 | 0 | 2 |
| Preimplantation genetic testing: a Practice Committee opinion | 27.3 | 0 | 2 |
| Techniques for ovarian tissue, whole ovary, oocyte and embryo cryopreservation | 27.3 | 0 | 2 |
| Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. | 27.3 | 0 | 2 |
| An evaluation of embryo, zygote and oocyte cryopreservation in assisted reproductive technology | 27.3 | 0 | 2 |
| Breast cancer and fertility preservation | 27.3 | 0 | 2 |
| Cancer and fertility preservation in Puerto Rico: a qualitative study of healthcare provider perceptions | 27.3 | 0 | 2 |
| Assisted reproduction and fertility preservation techniques in cancer patients | 27.3 | 0 | 2 |
| Fertility preservation in cancer patients using stored ovarian tissue: clinical aspects | 27.3 | 0 | 2 |
| Optimizing natural fertility | 27.3 | 0 | 2 |
| Fertility preservation in males with cancer: 16-year monocentric experience of sperm banking and post-thaw reproductive outcomes | 27.3 | 0 | 2 |
| Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy--a technique in its infancy but already successful in fertility preservation | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience | 27.3 | 0 | 2 |
| Fertility Preservation Options after Gonadotoxic Chemotherapy | 27.3 | 0 | 2 |
| Breast cancer and fertility preservation | 27.3 | 0 | 2 |
| Current approach to fertility preservation by embryo cryopreservation | 27.3 | 0 | 2 |
| Random start or emergency IVF/in vitro maturation: a new rapid approach to fertility preservation | 27.3 | 0 | 2 |
| Laparoscopic ovarian tissue harvesting for cryopreservation: an effective and safe procedure for fertility preservation | 27.3 | 0 | 2 |
| The promise of in vitro maturation in assisted reproduction and fertility preservation. | 27.3 | 0 | 2 |
| Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature | 27.3 | 0 | 2 |
| Oocyte cryopreservation as a fertility preservation measure for cancer patients | 27.3 | 0 | 2 |
| Elective single-embryo transfer | 27.3 | 0 | 2 |
| Cryopreservation of ovarian tissue for fertility preservation in young female oncological patients | 27.3 | 0 | 2 |
| Ovarian tissue and follicle transplantation as an option for fertility preservation | 27.3 | 0 | 2 |
| Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion | 27.3 | 0 | 2 |
| Cancer and fertility preservation: Barcelona consensus meeting | 27.3 | 0 | 2 |
| In vitro maturation: a committee opinion | 27.3 | 0 | 2 |
| The wobbly evidence base of reproductive medicine | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation: a committee opinion | 27.3 | 0 | 2 |
| Role of assisted hatching in in vitro fertilization: a guideline | 27.3 | 0 | 2 |
| Recommended practices for the management of embryology, andrology, and endocrinology laboratories: a committee opinion | 27.3 | 0 | 2 |
| Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review | 27.3 | 0 | 2 |
| Autotransplantation of cryopreserved ovarian tissue--effective method of fertility preservation in cancer patients. | 27.3 | 0 | 2 |
| Fertility preservation in the female cancer patient | 27.3 | 0 | 2 |
| Who should be offered sperm banking for fertility preservation? A survey of UK oncologists and haematologists. | 27.3 | 0 | 2 |
| Role of tubal surgery in the era of assisted reproductive technology: a committee opinion | 27.3 | 0 | 2 |
| Successful Pregnancy and Neobladder Subsequent to Muscle Invasive Bladder Cancer and Fertility Preserving Surgery: Case Report and Review of the Literature | 27.3 | 0 | 2 |
| Role of the mental health professional in education and support of the medical staff | 27.3 | 0 | 2 |
| Subclinical hypothyroidism in the infertile female population: a guideline | 27.3 | 0 | 2 |
| Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy | 27.3 | 0 | 2 |
| Sperm cryopreservation and assisted reproductive technology outcome in patients with spinal cord injury. | 27.3 | 0 | 2 |
| Fertility preservation in pre-pubertal girls with cancer: the role of ovarian tissue cryopreservation. | 27.3 | 0 | 2 |
| Fertility preservation in Turner syndrome | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation for Benign Gynecologic Disease: A Case of Ovarian Torsion and Review of the Literature | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Chapter 16 Directional Freezing of Ovarian Tissue and Freeze-Drying of Stem Cells for Fertility Preservation | 27.3 | 0 | 2 |
| A nationwide UK survey of female fertility preservation prior to cancer treatment | 27.3 | 0 | 2 |
| Maternal Racial and Ethnic Disparities in Neonatal Birth Outcomes With and Without Assisted Reproduction | 27.3 | 0 | 2 |
| Mature Oocyte Cryopreservation for Fertility Preservation | 27.3 | 0 | 2 |
| Female fertility preservation strategies: cryopreservation and ovarian tissue in vitro culture, current state of the art and future perspectives | 27.3 | 0 | 2 |
| Ewe Ovarian Tissue Vitrification: A Model for the Study of Fertility Preservation in Women. | 27.3 | 0 | 2 |
| Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates | 27.3 | 0 | 2 |
| Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices | 27.3 | 0 | 2 |
| Guidance on the limits to the number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Emergent Oocyte Cryopreservation with a Novel Ovarian Transposition Technique in a Colorectal Cancer Patient: A Combined Approach for Fertility Preservation. A Case Report | 27.3 | 0 | 2 |
| The Past, Present and Future of Fertility Preservation in Cancer Patients | 27.3 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with cancer | 27.3 | 0 | 2 |
| Sperm Banking: Fertility Preservation for Male Patients With Cancer | 27.3 | 0 | 2 |
| Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency | 27.3 | 0 | 2 |
| The role of sperm banking in fertility preservation | 27.3 | 0 | 2 |
| Cryopreservation of ovarian tissue for fertility preservation in a large cohort of young girls: focus on pubertal development | 27.3 | 0 | 2 |
| Ovarian Tissue Collection for Cryopreservation in Pediatric Age: Laparoscopic Technical Tips | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion | 27.3 | 0 | 2 |
| Sperm banking for fertility preservation: a 20-year experience | 27.3 | 0 | 2 |
| Factors affecting decision making about fertility preservation after cancer diagnosis: a qualitative study | 27.3 | 0 | 2 |
| In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. | 27.3 | 0 | 2 |
| Assisted reproductive techniques in Latin America: the Latin American Registry, 2013 | 27.3 | 0 | 2 |
| Assisted reproductive medicine in Poland --Fertility and Sterility Special Interest Group of the Polish Gynaecological Society (SPiN PTG) 2012 report | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Patient-physician communication barriers regarding fertility preservation among newly diagnosed cancer patients | 27.3 | 0 | 2 |
| Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in cancer patients | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Risk of ectopic pregnancy is linked to endometrial thickness in a retrospective cohort study of 8120 assisted reproduction technology cycles | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile Virus | 27.3 | 0 | 2 |
| Ethical issues in fertility preservation for adolescent cancer survivors: oocyte and ovarian tissue cryopreservation | 27.3 | 0 | 2 |
| Microsurgical vasoepididymostomy with sperm cryopreservation for future assisted reproduction | 27.3 | 0 | 2 |
| Position on reproductive donors and smallpox vaccine: a committee opinion | 27.3 | 0 | 2 |
| Current differences and consequences of legislation on practice of assisted reproductive technology in the Nordic countries. The Nordic Committee on Assisted Reproduction of the Scandinavian Federation of Societies of Obstetrics and Gynecology | 27.3 | 0 | 2 |
| Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012 | 27.3 | 0 | 2 |
| Safety in reproductive medicine: breadth, depth and discovery | 27.3 | 0 | 2 |
| Embryo Cryopreservation Following In-Vitro Maturation for Fertility Preservation in a Woman with Mullerian Adenosarcoma: A Case Report | 27.3 | 0 | 2 |
| Fertility preservation for trans men: frozen-thawed in vitro matured oocytes collected at the time of ovarian tissue processing exhibit normal meiotic spindles | 27.3 | 0 | 2 |
| Fertility preservation in women of the childbearing age: Indications and strategies | 27.3 | 0 | 2 |
| Cryopreservation ofin vitromatured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy | 27.3 | 0 | 2 |
| Fertility preservation in breast cancer patients: the state of art in 2014? | 27.3 | 0 | 2 |
| The Russian experience of autotransplantation of vitrified ovarian tissue to a cancer patient | 27.3 | 0 | 2 |
| Effect of necrostatin on mouse ovarian cryopreservation and transplantation | 27.3 | 0 | 2 |
| Optimal vitrification protocol for mouse ovarian tissue cryopreservation: effect of cryoprotective agents and in vitro culture on vitrified-warmed ovarian tissue survival | 27.3 | 0 | 2 |
| Restoring fertility with frozen ovarian tissue; experimental results | 27.3 | 0 | 2 |
| Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure | 27.3 | 0 | 2 |
| Human ovarian tissue preservation: is vitrification acceptable method for assisted reproduction? | 27.3 | 0 | 2 |
| Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation | 27.3 | 0 | 2 |
| Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation | 27.3 | 0 | 2 |
| Cancer and fertility preservation: international recommendations from an expert meeting | 27.3 | 0 | 2 |
| Oocyte cryopreservation after controlled ovarian hyperstimulation in mosaic Turner syndrome: another fertility preservation option in a dedicated UK clinic | 27.3 | 0 | 2 |
| Cryobanking of human ovarian tissue: do women still want their tissue stored beyond 5 years? | 27.3 | 0 | 2 |
| Repetitive oocyte donation: a committee opinion | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 27.3 | 0 | 2 |
| Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen | 27.3 | 0 | 2 |
| Ovarian tissue banking and fertility preservation in cancer patients: histological and immunohistochemical evaluation. | 27.3 | 0 | 2 |
| Is there any place for oocyte cryopreservation after cancer treatment? | 27.3 | 0 | 2 |
| Embryo transfer by reproductive endocrinology fellows vs attending physicians: are live birth rates comparable? | 27.3 | 0 | 2 |
| Evidence-based medicine and the role of the private sector in assisted reproduction: a response to Dr Fishel’s commentary ‘Evidenced-based medicine and the role of the National Health Service in assisted reproduction’ | 27.3 | 0 | 2 |
| Risk-sharing or refund programs in assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? | 27.3 | 0 | 2 |
| Developing a Referral System for Fertility Preservation Among Patients With Newly Diagnosed Cancer | 27.3 | 0 | 2 |
| Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Is sperm cryopreservation an option for fertility preservation in patients with spinal cord injury-induced anejaculation? | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer | 27.3 | 0 | 2 |
| Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin | 27.3 | 0 | 2 |
| Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Repo | 27.3 | 0 | 2 |
| Need for Comprehensive Counseling in Women Requesting Oocyte Cryopreservation | 27.3 | 0 | 2 |
| Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation | 27.3 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 27.3 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 27.3 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 27.3 | 0 | 2 |
| Fertility preservation with ovarian stimulation protocols prior to cancer treatment | 27.3 | 0 | 2 |
| No increase in autism-associated genetic events in children conceived by assisted reproduction | 27.3 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation in young cancer patients for fertility preservation | 27.3 | 0 | 2 |
| Medical egg freezing: the importance of a patient-centered approach to fertility preservation | 27.3 | 0 | 2 |
| Medical egg freezing and cancer patients' hopes: Fertility preservation at the intersection of life and death | 27.3 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Healthy Women | 27.3 | 0 | 2 |
| Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians | 27.3 | 0 | 2 |
| Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence | 27.3 | 0 | 2 |
| Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Financial "risk-sharing" or refund programs in assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Parental influences on sperm banking attempts among adolescent males newly diagnosed with cancer | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1999 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1998 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Single-Incision Laparoscopic Surgery for Ovarian Tissue Cryopreservation | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation and retransplantation – what do patients think about it? | 27.3 | 0 | 2 |
| A Focus on Maternal Health Before Assisted Reproduction: Results From a Pilot Survey of Canadian IVF Medical Directors | 27.3 | 0 | 2 |
| New methods to improve the safety assessment of cryopreserved ovarian tissue for fertility preservation in breast cancer patients | 27.3 | 0 | 2 |
| Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients | 27.3 | 0 | 2 |
| Assisted reproductive technology in reproductive medicine - possibilities and limitations | 27.3 | 0 | 2 |
| Fertility Preservation Services for Women With Newly Diagnosed Cancer: A National Assessment | 27.3 | 0 | 2 |
| Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation | 27.3 | 0 | 2 |
| Fertility Preservation Before Cancer Treatment: Options, Strategies, and Resources | 27.3 | 0 | 2 |
| Fertility Preservation Through Oocyte Cryopreservation in a Patient with Ovarian Dysgerminocarcinoma: A Case Report | 27.3 | 0 | 2 |
| Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield | 27.3 | 0 | 2 |
| Left Out in the Cold: Arguments Against Non-Medical Oocyte Cryopreservation | 27.3 | 0 | 2 |
| Transplantation of mouse ovarian tissue: Comparison of the transplantation sites | 27.3 | 0 | 2 |
| Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation and Transplantation: A Realistic, Effective Technology for Fertility Preservation | 27.3 | 0 | 2 |
| Developmental competence of oocytes isolated from surplus medulla tissue in connection with cryopreservation of ovarian tissue for fertility preservation | 27.3 | 0 | 2 |
| Recommendations for gamete and embryo donation: a committee opinion | 27.3 | 0 | 2 |
| Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 27.3 | 0 | 2 |
| Fertility preservation utilizing controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 27.3 | 0 | 2 |
| A transportation network for human ovarian tissue is indispensable to success for fertility preservation. | 27.3 | 0 | 2 |
| Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. | 27.3 | 0 | 2 |
| 2008 Guidelines for gamete and embryo donation: a Practice Committee report | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| Oocyte cryopreservation as alternative to embryo cryopreservation - some pertinent ethical concerns | 27.3 | 0 | 2 |
| Response to the Human Fertilisation and Embryology Authority's consultation document on research and fertility treatment using human ova and ovarian tissue obtained from live women, cadavers or fetuses | 27.3 | 0 | 2 |
| Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. | 27.3 | 0 | 2 |
| Evaluation of quantitative polymerase chain reaction markers for the detection of breast cancer cells in ovarian tissue stored for fertility preservation | 27.3 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 27.3 | 0 | 2 |
| Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark | 27.3 | 0 | 2 |
| 1995 assisted reproductive technology success rates: national summary and fertility clinic report. | 27.3 | 0 | 2 |
| Fertility preservation in children newly diagnosed with cancer: existing standards of practice in Australia and New Zealand. | 27.3 | 0 | 2 |
| 2006 Guidelines for Gamete and Embryo Donation | 27.3 | 0 | 2 |
| Elements to be considered in obtaining informed consent for ART. | 27.3 | 0 | 2 |
| Encouraging results despite complexity of multidisciplinary care of HIV-infected women using assisted reproduction techniques | 27.3 | 0 | 2 |
| Use of fetal oocytes in assisted reproduction | 27.3 | 0 | 2 |
| Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro | 27.3 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 27.3 | 0 | 2 |
| Limited Value of Ovarian Function Markers following Orthotopic Transplantation of Ovarian Tissue after Gonadotoxic Treatment | 27.3 | 0 | 2 |
| Discussing fertility preservation at the time of cancer diagnosis: Dissatisfaction of young females | 27.3 | 0 | 2 |
| A comprehensive method for the conservation of mouse strains combining natural breeding, sperm cryopreservation and assisted reproductive technology | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| AIDA for reproductive medicine and the fertility clinic | 27.3 | 0 | 2 |
| Facing a cancer diagnosis: empowering parents to speak with adolescents about sperm banking | 27.3 | 0 | 2 |
| AIUM practice guideline for ultrasonography in reproductive medicine | 27.3 | 0 | 2 |
| Clinical effects of oocyte cryopreservation in assisted reproduction technology | 27.3 | 0 | 2 |
| Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 27.3 | 0 | 2 |
| Provider Influences on Sperm Banking Outcomes Among Adolescent Males Newly Diagnosed With Cancer | 27.3 | 0 | 2 |
| A national study of the provision of oncology sperm banking services among Canadian fertility clinics | 27.3 | 0 | 2 |
| Sperm cryopreservation in adolescents and young adults with cancer: results of the French national sperm banking network (CECOS) | 27.3 | 0 | 2 |
| Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors | 27.3 | 0 | 2 |
| Oocyte/embryo cryopreservation before chemotherapy for breast cancer | 27.3 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Clinical practice guidelines for fertility preservation in young women undergoing gonadotoxic treatment: an overview and critical appraisal of methodological quality and content | 27.3 | 0 | 2 |
| Abstracts for 2018 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Deliveries following fertility preservation by ovarian tissue cryopreservation without autotransplantation-what should be expected? | 27.3 | 0 | 2 |
| Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Re: Parental Influences on Sperm Banking Attempts among Adolescent Males Newly Diagnosed with Cancer | 27.3 | 0 | 2 |
| Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer | 27.3 | 0 | 2 |
| Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Gender reassignment and assisted reproduction: An ethical analysis. Bristol Centre for Reproductive Medicine Ethics Advisory Committee | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction. The Ethics Committee of the American Society for Reproductive Medicine | 27.3 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a nationwide survey of US Obstetrics and Gynecology residents | 27.3 | 0 | 2 |
| La cryopréservation ovocytaire va-t-elle relancer l’intérêt du prélèvement chirurgical de spermatozoïdes synchrone du recueil ovocytaire en cas d’azoospermie non obstructive ? | 27.3 | 0 | 2 |
| Limited importance of pre-embryo pronuclear morphology (zygote score) in assisted reproduction outcome in the absence of embryo cryopreservation | 27.3 | 0 | 2 |
| Prevalence of abnormal semen analysis and levels of adherence with fertility preservation in men undergoing therapy for newly diagnosed cancer: A retrospective study in 2906 patients | 27.3 | 0 | 2 |
| Oocyte Cryopreservation | 27.3 | 0 | 2 |
| Preserving fertility in women with cancer (PreFer): Decision-making and patient-reported outcomes in women offered egg and embryo freezing prior to cancer treatment | 27.3 | 0 | 2 |
| Fertility Preservation With Ovarian Tissue Freezing | 27.3 | 0 | 2 |
| Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool | 27.3 | 0 | 2 |
| Abstracts for 2017 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| What advice should we give our patients to preserve their fertility and avoid needing oocyte donation in the future? - A Social Fertility Preservation program | 27.3 | 0 | 2 |
| Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients | 27.3 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation for Fertility Preservation | 27.3 | 0 | 2 |
| Ovarian Tissue Freezing For Fertility Preservation | 27.3 | 0 | 2 |
| Fertility Preservation by Ovarian and Oocyte Cryopreservation | 27.3 | 0 | 2 |
| Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer | 27.3 | 0 | 2 |
| Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation | 27.3 | 0 | 2 |
| Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo | 27.3 | 0 | 2 |
| Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment | 27.3 | 0 | 2 |
| Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment | 27.3 | 0 | 2 |
| Newborns From Patients Treated With ART (Assisted Reproductive Technology) | 27.3 | 0 | 2 |
| The Experience of TYAC Offered Ovarian Tissue Cryopreservation | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation in Children | 27.3 | 0 | 2 |
| Sperm banking before chemotherapy or radiotherapy for cancer | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1994 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Reproductive medicine and assisted reproduction--present status and perspectives in the Czech Republic | 27.3 | 0 | 2 |
| Female fertility preservation before sterilizing treatment: contribution of ovarian tissue cryopreservation | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1997 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Sperm cryopreservation in adolescents with newly diagnosed cancer | 27.3 | 0 | 2 |
| A rational basis for antiphospholipid antibody testing and selective immunotherapy in assisted reproduction: a rebuttal to the American Society for Reproductive Medicine Practice opinion. American Society for Reproductive Immunology Antiphospholipid | 27.3 | 0 | 2 |
| Fertility preservation by ovarian tissue cryopreservation | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Assisted Reproductive Technology in the United States and Canada: 1995 Results Generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Evaluation of Fertility in Young Adults Who Did or Did Not Store Testicular Tissue Before a Treatment Possibly Leading to Later Fertility Problems. | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Preimplantation genetic diagnosis | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| [Questionnaire survey in Japan for sperm cryopreservation before chemotherapy ] | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation as a perspective for fertility preservation | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society for Assisted Reproductive Technology/American Society for Reproductive Medicine recommendation | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Sperm banking before gonadotoxic treatment--11-years experience | 27.3 | 0 | 2 |
| Guidelines on the number of embryos transferred | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Blastocyst production and transfer in clinical assisted reproduction | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction | 27.3 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Adolescents treated for cancer and fertility preservation. Psychological aspects | 27.3 | 0 | 2 |
| ACOG Committee Opinion No. 405: ovarian tissue and oocyte cryopreservation | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility: depth of the problem and possible solutions | 27.3 | 0 | 2 |
| Professionals' views on the issues and challenges arising from providing a fertility preservation service through sperm banking to teenage males with cancer | 27.3 | 0 | 2 |
| Response by the leadership of the Society of Assisted Reproductive Technology (SART) to the article “Assisted Reproduction and Choices in the Biotech Age” | 27.3 | 0 | 2 |
| Preimplantation genetic testing: a Practice Committee opinion | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI) | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Young males' experiences of sperm banking following a cancer diagnosis - a qualitative study | 27.3 | 0 | 2 |
| Committee opinion: role of tubal surgery in the era of assisted reproductive technology | 27.3 | 0 | 2 |
| Testicular sperm cryopreservation for male fertility preservation | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: an ASRM Practice Committee guideline | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: a committee opinion | 27.3 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Sperm banking in adolescent males with nephrotic syndrome: defining the limits of access to fertility preservation | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor? | 27.3 | 0 | 2 |
| Criteria for number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Possibilities of cryopreservation of ovarian tissue for fertility preservation in cancer patients | 27.3 | 0 | 2 |
| Success and challenges in fertility preservation after ovarian tissue grafting | 27.3 | 0 | 2 |
| AIUM Practice Guideline for the Performance of a Focused Reproductive Endocrinology and Infertility Scan | 27.3 | 0 | 2 |
| Treatment of advanced ovarian carcinoma: surgery before chemotherapy or chemotherapy before surgery? | 27.3 | 0 | 2 |
| Cryopreservation and transplantation of ovarian tissue exclusively to postpone menopause: technically possible but endocrinologically doubtful | 27.3 | 0 | 2 |
| Fertility preservation in breast cancer patients by embryo cryopreservation after ovarian stimulation with letrozole and FSH | 27.3 | 0 | 2 |
| Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise | 27.3 | 0 | 2 |
| Use of reproductive technology for sex selection for nonmedical reasons | 27.3 | 0 | 2 |
| Processing of semen by density gradient centrifugation selects spermatozoa with longer telomeres for assisted reproduction techniques | 27.3 | 0 | 2 |
| [Assisted Reproductive Technology in Female Transplant Recipients: Experience of a Reproductive Medicine Unit and Literature Review] | 27.3 | 0 | 2 |
| Cryoconservation of ovarian tissue: indications and outcome of the patients | 27.3 | 0 | 2 |
| The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion | 27.3 | 0 | 2 |
| Attitude towards ovarian tissue and oocyte cryopreservation for non-medical reasons: a cross-sectional study | 27.3 | 0 | 2 |
| Patient factors associated with sperm cryopreservation among at-risk adolescents newly diagnosed with cancer | 27.3 | 0 | 2 |
| Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion | 27.3 | 0 | 2 |
| Reporting assisted reproductive technology success rates on Australian and New Zealand fertility clinic websites | 27.3 | 0 | 2 |
| Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer | 27.3 | 0 | 2 |
| Minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Cryopreservation of Ovarian Tissue: Opportunities Beyond Fertility Preservation and a Positive View Into the Future | 27.3 | 0 | 2 |
| Assisted Reproductive Technology and the Reproductive Endocrinology and Infertility Specialist in the U.S. Military | 27.3 | 0 | 2 |
| Factors associated with successful pregnancy in women of late reproductive age with uterine fibroids who undergo embryo cryopreservation before surgery | 27.3 | 0 | 2 |
| Patient non-attendance at urgent referral appointments for suspected cancer and its links to cancer diagnosis and one year mortality: A cohort study of patients referred on the Two Week Wait pathway | 27.3 | 0 | 2 |
| Re: Assisted Reproductive Technology Outcomes in Female-to-Male Transgender Patients Compared with Cisgender Patients: A New Frontier in Reproductive Medicine | 27.3 | 0 | 2 |
| Androgenicity and fertility treatment in women with unexplained infertility | 27.3 | 0 | 2 |
| Ovarian stimulation and assisted reproductive technology outcomes in women transplanted with cryopreserved ovarian tissue: a systematic review | 27.3 | 0 | 2 |
| Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine | 27.3 | 0 | 2 |
| Assessment of Turkey IVF (In Vitro Fertilization) websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 27.3 | 0 | 2 |
| Optimizing the opportunity for female fertility preservation in a limited time-frame for patients with cancer using in vitro maturation and ovarian tissue cryopreservation | 27.3 | 0 | 2 |
| Recognition and attitudes of Japanese hematologists on sperm banking before chemotherapy: present status from nationwide questionnaire survey | 27.3 | 0 | 2 |
| Concept Paper on the Technique of Cryopreservation, Removal and Transplantation of Ovarian Tissue for Fertility Preservation | 27.3 | 0 | 2 |
| Laparoscopic ovarian tissue harvesting and orthotopic ovarian cortex grafting for fertility preservation: less is more | 27.3 | 0 | 2 |
| [Epithelial ovarian cancer and fertility preservation: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis | 27.3 | 0 | 2 |
| Abstracts presented at the 2019 Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology | 27.3 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 27.3 | 0 | 2 |
| [Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department] | 27.3 | 0 | 2 |
| FERTILITY PRESERVATION: Freezing of ovarian tissue and clinical opportunities | 27.3 | 0 | 2 |
| Importance and safety of autologous sperm cryopreservation for fertility preservation in young male patients with cancer | 27.3 | 0 | 2 |
| TurnerFertility trial: PROTOCOL for an observational cohort study to describe the efficacy of ovarian tissue cryopreservation for fertility preservation in females with Turner syndrome | 27.3 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with ovarian endometriosis | 27.3 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 27.3 | 0 | 2 |
| EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation and transplantation: what advances are necessary for this fertility preservation modality to no longer be considered experimental? | 27.3 | 0 | 2 |
| Variation in follicle health and development in cultured cryopreserved ovarian cortical tissue: a study of ovarian tissue from patients undergoing fertility preservation | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion | 27.3 | 0 | 2 |
| A Chinese practice guideline of the assisted reproductive technology strategies for women with advanced age | 27.3 | 0 | 2 |
| FERTILITY PRESERVATION: Follicle reserve loss in ovarian tissue transplantation | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives | 27.3 | 0 | 2 |
| Oocyte and ovarian tissue cryopreservation in European countries: statutory background, practice, storage and use | 27.3 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men's roles in women's fertility preservation | 27.3 | 0 | 2 |
| Importance of ovarian tissue cryopreservation in fertility preservation and anti-aging treatment | 27.3 | 0 | 2 |
| Cancer and fertility preservation in females: where we stand and where we are heading | 27.3 | 0 | 2 |
| Sperm cryopreservation prior to gonadotoxic treatment: experience of a single academic centre over 4 decades | 27.3 | 0 | 2 |
| Ovarian tissue health after laparoscopic unilateral oophorectomy: A porcine model for establishing optimized fertility preservation techniques in children | 27.3 | 0 | 2 |
| College of American Pathologists and American Society for Reproductive Medicine accreditation of assisted reproductive technology (ART) laboratories is associated with a decrease in take home baby rates of reporting ART laboratories | 27.3 | 0 | 2 |
| Erratum to: Relationship between oxidative stress and clinical pregnancy in assisted reproductive technology treatment cycles | 27.3 | 0 | 2 |
| Guidelines on the number of embryos transferred | 27.3 | 0 | 2 |
| [FERTILITY PRESERVATION BY CRYOPRESERVATION OF TESTICULAR TISSUE FROM PRE-PUBERTAL BOYS UNDERGOING GONADOTOXIC TREATMENT - PRELIMINARY RESULTS] | 27.3 | 0 | 2 |
| Success and challenges in fertility preservation after ovarian tissue grafting | 27.3 | 0 | 2 |
| [Successful ovarian tissue transplantation in woman with premature ovarian failure after gonadotoxic treatment] | 27.3 | 0 | 2 |
| Fertility preservation for children and adolescents before gonadotoxic treatment | 27.3 | 0 | 2 |
| Repetitive oocyte donation: a committee opinion | 27.3 | 0 | 2 |
| Attitudes and experiences of health care professionals when caring for transgender men undergoing fertility preservation by egg freezing: a qualitative study | 27.3 | 0 | 2 |
| Importance of early and precise ascertainment of mosaic Turner syndrome for fertility preservation and assisted reproduction counseling | 27.3 | 0 | 2 |
| The quality of information about elective oocyte cryopreservation (EOC) on Australian fertility clinic websites | 27.3 | 0 | 2 |
| Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey | 27.3 | 0 | 2 |
| Intracytoplasmic sperm injection (ICSI) for non-male factor indications: a committee opinion | 27.3 | 0 | 2 |
| Cryostorage of reproductive tissues in the in vitro fertilization laboratory: a committee opinion | 27.3 | 0 | 2 |
| Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue | 27.3 | 0 | 2 |
| IVM Survey Among Reproductive Medicine Specialists | 27.3 | 0 | 2 |
| Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes | 27.3 | 0 | 2 |
| New insights for fertility preservation by ovarian tissue cryopreservation and transplantation in pediatric cancer patients | 27.3 | 0 | 2 |
| How are women supported in making decisions regarding fertility preservation after a breast cancer diagnosis? | 27.3 | 0 | 2 |
| Fertility clinic advertising in the United States: is the Society for Assisted Reproductive Technology oversight of advertising policy effective? | 27.3 | 0 | 2 |
| Slow-Freezing Cryopreservation Ensures High Ovarian Tissue Quality Followed by In Vivo and In Vitro Methods and Is Safe for Fertility Preservation | 27.3 | 0 | 2 |
| Cryopreservation of Oocytes Retrieved from Ovarian Tissue to Optimize Fertility Preservation in Prepubertal Girls and Women | 27.3 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 27.3 | 0 | 2 |
| Fertility Preservation: The Challenge of Freezing and Transplanting Ovarian Tissue | 27.3 | 0 | 2 |
| The marketing of elective egg freezing: A content, cost and quality analysis of UK fertility clinic websites | 27.3 | 0 | 2 |
| In vitro maturation: a committee opinion | 27.3 | 0 | 2 |
| When laparoscopy for fertility preservation prior to gonadotoxic treatment of an anterior mediastinal mass is a dilemma: A case report | 27.3 | 0 | 2 |
| “Add-Ons” for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics’ Websites? | 27.3 | 0 | 2 |
| A modified hydrostatic microfluidic pumpless device for in vitro murine ovarian tissue culture as research model for fertility preservation | 27.3 | 0 | 2 |
| Planned oocyte cryopreservation for fertility preservation | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation and transplantation for fertility preservation | 27.3 | 0 | 2 |
| A Federated Blockchain Approach for Fertility Preservation and Assisted Reproduction in Smart Cities | 27.3 | 0 | 2 |
| Analysis of Fertility Preservation by Ovarian Tissue Cryopreservation in Pediatric Children in China | 27.3 | 0 | 2 |
| Fertility Preservation for Adolescent and Young Adult Transmen: A Case Series and Insights on Oocyte Cryopreservation | 27.3 | 0 | 2 |
| Optimizing Physical Function Before Cancer Surgery in Older People at Risk | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal) | 27.3 | 0 | 2 |
| Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal) | 27.3 | 0 | 2 |
| A retrospective study of ovarian tissue cryopreservation in female patients with hematological diseases for fertility preservation | 27.3 | 0 | 2 |
| Oncologic oocyte cryopreservation for fertility preservation: national trends and comparison of cycle characteristics between women with and without cancer | 27.3 | 0 | 2 |
| Sperm cryopreservation for fertility preservation in men with non-malignant diseases | 27.3 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men’s hidden roles in women’s fertility preservation | 27.3 | 0 | 2 |
| Sperm cryopreservation for fertility preservation in male patients with cancer at a single-center in Japan | 27.3 | 0 | 2 |
| Ovarian tissue cryopreservation: A fertility preservation option for gynecologic oncology patients | 27.3 | 0 | 2 |
| Recent Advances in Reproductive Endocrinology: Implications for Fertility Treatment in Gynecology | 27.3 | 0 | 2 |
| The challenges of ovarian tissue banking for fertility preservation and restoration | 27.3 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a survey of OB/GYN residents across united states | 27.3 | 0 | 2 |
| Fertility preservation decision-making prior to gonadotoxic treatment: an analysis of 451 patients | 27.3 | 0 | 2 |
| Ongoing Review of Clinical Outcomes Following Ovarian Tissue Cryopreservation for Fertility Preservation | 27.3 | 0 | 2 |
| Fertility preservation methods in women subjected to gonadotoxic treatment or gonadoreducing surgery | 27.3 | 0 | 2 |
| Cyprus Fertina IVF Clinic | 27.3 | 0 | 2 |
| planned oocyte cryopreservation | 27.3 | 0 | 2 |
| Genera PMA | 27.3 | 0 | 2 |
| Heinrich Heine | 25.8 | 1 | 0 |
| German Wikipedia | 25.8 | 1 | 0 |
| Uwe Timm | 25.8 | 1 | 0 |
| Georg Ratzinger | 25.8 | 1 | 0 |
| Frontiers Media | 25.8 | 1 | 0 |
| National Center for Biotechnology Information | 25.8 | 1 | 0 |
| Martin Jankowski | 25.8 | 1 | 0 |
| Antje Rávic Strubel | 25.8 | 1 | 0 |
| Helmut Reichelt | 25.8 | 1 | 0 |
| Michael Meister | 25.8 | 1 | 0 |
| Martin Suter | 25.8 | 1 | 0 |
| Heinz Höhne | 25.8 | 1 | 0 |
| Jean Ziegler | 25.8 | 1 | 0 |
| University of California, Davis | 25.8 | 1 | 0 |
| Arnold Schoenberg | 25.8 | 1 | 0 |
| Q180686 | 25.8 | 1 | 0 |
| Livestrong Foundation | 25.8 | 1 | 0 |
| Zeruya Shalev | 25.8 | 1 | 0 |
| Maya Hakvoort | 25.8 | 1 | 0 |
| Oregon Health and Science University | 25.8 | 1 | 0 |
| Harold E. Varmus | 25.8 | 1 | 0 |
| Juan Atkins | 25.8 | 1 | 0 |
| Phyllis Dillon | 25.8 | 1 | 0 |
| Julius Weismann | 25.8 | 1 | 0 |
| American Cancer Society | 25.8 | 1 | 0 |
| HomoloGene | 25.8 | 1 | 0 |
| Nils Schmid | 25.8 | 1 | 0 |
| Andrascz Weigoni | 25.8 | 1 | 0 |
| Andrea Röpke | 25.8 | 1 | 0 |
| Andreas Raselius | 25.8 | 1 | 0 |
| Martin Peerson | 25.8 | 1 | 0 |
| Carmen Cavallaro | 25.8 | 1 | 0 |
| Anna Kaleri | 25.8 | 1 | 0 |
| Antje Szillat | 25.8 | 1 | 0 |
| Johns Hopkins School of Medicine | 25.8 | 1 | 0 |
| Blood | 25.8 | 1 | 0 |
| GenBank | 25.8 | 1 | 0 |
| Tell Me Why | 25.8 | 1 | 0 |
| NewYork–Presbyterian Hospital | 25.8 | 1 | 0 |
| Bruno Preisendörfer | 25.8 | 1 | 0 |
| University of California, San Francisco | 25.8 | 1 | 0 |
| Dana–Farber Cancer Institute | 25.8 | 1 | 0 |
| Detlef Opitz | 25.8 | 1 | 0 |
| Journal of Virology | 25.8 | 1 | 0 |
| Pennsylvania Hospital | 25.8 | 1 | 0 |
| Rolf Stolz | 25.8 | 1 | 0 |
| Franz H. Mautner | 25.8 | 1 | 0 |
| Entrez | 25.8 | 1 | 0 |
| Greg Phillinganes | 25.8 | 1 | 0 |
| Esther Kinsky | 25.8 | 1 | 0 |
| Frank Hammer | 25.8 | 1 | 0 |
| Friedel Schuster | 25.8 | 1 | 0 |
| Johns Hopkins Hospital | 25.8 | 1 | 0 |
| Gerhard Schreiber | 25.8 | 1 | 0 |
| Gernot Wolfram | 25.8 | 1 | 0 |
| Krixi, Kraxi und die Kroxn | 25.8 | 1 | 0 |
| Svealena Kutschke | 25.8 | 1 | 0 |
| polymyalgia rheumatica | 25.8 | 1 | 0 |
| Lars Rohwer | 25.8 | 1 | 0 |
| Memorial Sloan Kettering Cancer Center | 25.8 | 1 | 0 |
| Nanoscale Research Letters | 25.8 | 1 | 0 |
| eLife | 25.8 | 1 | 0 |
| PeerJ | 25.8 | 1 | 0 |
| Biophysical Journal | 25.8 | 1 | 0 |
| UCLA Ronald Reagan Medical Center | 25.8 | 1 | 0 |
| Frontiers in Neuroscience | 25.8 | 1 | 0 |
| Journal of Cardiovascular Magnetic Resonance | 25.8 | 1 | 0 |
| Mayo Clinic Hospital — Rochester | 25.8 | 1 | 0 |
| Simon Pearce | 25.8 | 1 | 0 |
| The Dresden Soul Symphony | 25.8 | 1 | 0 |
| Till Steffen | 25.8 | 1 | 0 |
| Frontiers in Physiology | 25.8 | 1 | 0 |
| Frontiers in Genetics | 25.8 | 1 | 0 |
| Vattikuti Urology Institute | 25.8 | 1 | 0 |
| Cancer Biology and Therapy | 25.8 | 1 | 0 |
| Wilfried F. Schoeller | 25.8 | 1 | 0 |
| Cancer Imaging | 25.8 | 1 | 0 |
| Bioscience Reports | 25.8 | 1 | 0 |
| ACS Chemical Neuroscience | 25.8 | 1 | 0 |
| Acta Histochemica et Cytochemica | 25.8 | 1 | 0 |
| American Society of Clinical Oncology | 25.8 | 1 | 0 |
| Aging | 25.8 | 1 | 0 |
| Baylor College of Medicine | 25.8 | 1 | 0 |
| Brigham and Women's Hospital | 25.8 | 1 | 0 |
| GeneReviews | 25.8 | 1 | 0 |
| Grossman School of Medicine | 25.8 | 1 | 0 |
| Henry Ford Hospital | 25.8 | 1 | 0 |
| Biomicrofluidics | 25.8 | 1 | 0 |
| Journal of Experimental Medicine | 25.8 | 1 | 0 |
| Molecular and Cellular Biology | 25.8 | 1 | 0 |
| UC San Diego Health System | 25.8 | 1 | 0 |
| Weill Cornell Medicine | 25.8 | 1 | 0 |
| Eugene Koonin | 25.8 | 1 | 0 |
| GlobalGiving | 25.8 | 1 | 0 |
| Department of Health | 25.8 | 1 | 0 |
| Johns Hopkins All Children's Hospital | 25.8 | 1 | 0 |
| Henry Ford Jackson Hospital | 25.8 | 1 | 0 |
| American Academy of Family Physicians | 25.8 | 1 | 0 |
| CURE | 25.8 | 1 | 0 |
| Canadian Journal of Gastroenterology & Hepatology | 25.8 | 1 | 0 |
| Canadian Respiratory Journal | 25.8 | 1 | 0 |
| Cancer Information Service | 25.8 | 1 | 0 |
| Cancer Treatment Centers of America | 25.8 | 1 | 0 |
| Carilion New River Valley Medical Center | 25.8 | 1 | 0 |
| Carilion Roanoke Memorial Hospital | 25.8 | 1 | 0 |
| Cerebral Cortex | 25.8 | 1 | 0 |
| City of Hope National Medical Center | 25.8 | 1 | 0 |
| Cn3D | 25.8 | 1 | 0 |
| Consensus CDS Project | 25.8 | 1 | 0 |
| Conserved Domain Database | 25.8 | 1 | 0 |
| CytoJournal | 25.8 | 1 | 0 |
| Diabetes Care | 25.8 | 1 | 0 |
| Emory Healthcare | 25.8 | 1 | 0 |
| Emory University Hospital | 25.8 | 1 | 0 |
| Emory University Hospital Midtown | 25.8 | 1 | 0 |
| Enid A. Haupt Glass Garden | 25.8 | 1 | 0 |
| Eukaryotic Cell | 25.8 | 1 | 0 |
| European Journal of Medical Research | 25.8 | 1 | 0 |
| Evidence-based Complementary and Alternative Medicine | 25.8 | 1 | 0 |
| M Health Fairview | 25.8 | 1 | 0 |
| Genetic codes | 25.8 | 1 | 0 |
| Geriatric orthopaedic surgery & rehabilitation | 25.8 | 1 | 0 |
| Global Health Action | 25.8 | 1 | 0 |
| HSS Journal | 25.8 | 1 | 0 |
| Harborview Medical Center | 25.8 | 1 | 0 |
| Hospital of the University of Pennsylvania | 25.8 | 1 | 0 |
| Howard County General Hospital | 25.8 | 1 | 0 |
| IBIS | 25.8 | 1 | 0 |
| Indian Journal of Nephrology | 25.8 | 1 | 0 |
| Indian Journal of Psychological Medicine | 25.8 | 1 | 0 |
| International Journal of Clinical and Experimental Medicine | 25.8 | 1 | 0 |
| International Journal of Clinical and Experimental Pathology | 25.8 | 1 | 0 |
| Journal of Cutaneous and Aesthetic Surgery | 25.8 | 1 | 0 |
| Journal of Medical Ethics | 25.8 | 1 | 0 |
| Journal of the Experimental Analysis of Behavior | 25.8 | 1 | 0 |
| Journal of the International AIDS Society | 25.8 | 1 | 0 |
| UCLA Jules Stein Eye Institute | 25.8 | 1 | 0 |
| Blood Cancer United | 25.8 | 1 | 0 |
| Long Island Jewish Medical Center | 25.8 | 1 | 0 |
| Lucile Packard Children's Hospital | 25.8 | 1 | 0 |
| Mayo Clinic Hospital – Jacksonville | 25.8 | 1 | 0 |
| Mayo School of Health Sciences | 25.8 | 1 | 0 |
| McGill Journal of Medicine | 25.8 | 1 | 0 |
| Middle East Cancer Consortium | 25.8 | 1 | 0 |
| Milbank Quarterly | 25.8 | 1 | 0 |
| Molecular Medicine | 25.8 | 1 | 0 |
| Morgan Stanley Children's Hospital | 25.8 | 1 | 0 |
| NYU Langone Health | 25.8 | 1 | 0 |
| National Comprehensive Cancer Network | 25.8 | 1 | 0 |
| NewYork-Presbyterian Healthcare System | 25.8 | 1 | 0 |
| Lower Manhattan Hospital | 25.8 | 1 | 0 |
| Weill Cornell Medical Center | 25.8 | 1 | 0 |
| Northwest Hospital & Medical Center | 25.8 | 1 | 0 |
| Oregon Health & Science University School of Dentistry | 25.8 | 1 | 0 |
| Oregon Health & Science University Hospital | 25.8 | 1 | 0 |
| Penn Presbyterian Medical Center | 25.8 | 1 | 0 |
| Perelman Center for Advanced Medicine | 25.8 | 1 | 0 |
| Psychological Reports | 25.8 | 1 | 0 |
| RefSeq | 25.8 | 1 | 0 |
| Saint Joseph's Hospital | 25.8 | 1 | 0 |
| Scheie Eye Institute | 25.8 | 1 | 0 |
| Sexually Transmitted Infections | 25.8 | 1 | 0 |
| Sibley Memorial Hospital | 25.8 | 1 | 0 |
| Q7541087 | 25.8 | 1 | 0 |
| Stanford Hospital and Clinics | 25.8 | 1 | 0 |
| Stanford University Medical Center | 25.8 | 1 | 0 |
| The Journal of Chiropractic Education | 25.8 | 1 | 0 |
| UCLA Santa Monica Medical Center | 25.8 | 1 | 0 |
| UCSF Medical Center | 25.8 | 1 | 0 |
| University of Wisconsin Carbone Cancer Center | 25.8 | 1 | 0 |
| UniGene | 25.8 | 1 | 0 |
| Univec | 25.8 | 1 | 0 |
| University Neuropsychiatric Institute | 25.8 | 1 | 0 |
| University Orthopaedic Center | 25.8 | 1 | 0 |
| University of Chicago Comprehensive Cancer Center | 25.8 | 1 | 0 |
| UChicago Medicine | 25.8 | 1 | 0 |
| University of Pennsylvania Health System | 25.8 | 1 | 0 |
| University of Utah Hospital | 25.8 | 1 | 0 |
| University of Washington Medical Center | 25.8 | 1 | 0 |
| University of Washington School of Medicine | 25.8 | 1 | 0 |
| University of Wisconsin Hospital and Clinics | 25.8 | 1 | 0 |
| Victor Velculescu | 25.8 | 1 | 0 |
| WWAMI Regional Medical Education Program | 25.8 | 1 | 0 |
| Taxonomy database of the U.S. National Center for Biotechnology Information | 25.8 | 1 | 0 |
| Sidra Medical and Research Center | 25.8 | 1 | 0 |
| Stem Cell Research & Therapy | 25.8 | 1 | 0 |
| Johns Hopkins Bayview Medical Center | 25.8 | 1 | 0 |
| WikiCon | 25.8 | 1 | 0 |
| Theodore H. Schwartz | 25.8 | 1 | 0 |
| MMDB | 25.8 | 1 | 0 |
| Tissue Barriers | 25.8 | 1 | 0 |
| Small GTPases (journal) | 25.8 | 1 | 0 |
| The Eugenics Review | 25.8 | 1 | 0 |
| Translational Psychiatry | 25.8 | 1 | 0 |
| Molecular Autism | 25.8 | 1 | 0 |
| Physiological Reports | 25.8 | 1 | 0 |
| Cancer Control | 25.8 | 1 | 0 |
| Frontiers in Human Neuroscience | 25.8 | 1 | 0 |
| Physiotherapy Canada | 25.8 | 1 | 0 |
| Clinical and Developmental Immunology | 25.8 | 1 | 0 |
| Journal of Nematology | 25.8 | 1 | 0 |
| Journal of Physiological Anthropology | 25.8 | 1 | 0 |
| The Behavior Analyst | 25.8 | 1 | 0 |
| Advances in Pharmacological Sciences | 25.8 | 1 | 0 |
| Medical Science Monitor | 25.8 | 1 | 0 |
| The World Allergy Organization Journal | 25.8 | 1 | 0 |
| Integrative Medicine | 25.8 | 1 | 0 |
| Addiction Science and Clinical Practice | 25.8 | 1 | 0 |
| Journal of Human Virology | 25.8 | 1 | 0 |
| Hong Kong Medical Journal | 25.8 | 1 | 0 |
| Molecular Cytogenetics | 25.8 | 1 | 0 |
| Organogenesis | 25.8 | 1 | 0 |
| Clinical Diabetes | 25.8 | 1 | 0 |
| Journal of the American Association for Laboratory Animals | 25.8 | 1 | 0 |
| Journal of Children's Orthopaedics | 25.8 | 1 | 0 |
| Learning and Memory | 25.8 | 1 | 0 |
| Environmental Health Insights | 25.8 | 1 | 0 |
| Tobacco Control | 25.8 | 1 | 0 |
| American Journal of Tropical Medicine and Hygiene | 25.8 | 1 | 0 |
| Genome Integrity | 25.8 | 1 | 0 |
| Mobile DNA | 25.8 | 1 | 0 |
| Silence: a journal of RNA regulation | 25.8 | 1 | 0 |
| Frontiers in Neurology | 25.8 | 1 | 0 |
| mBio | 25.8 | 1 | 0 |
| Journal of Laboratory Physicians | 25.8 | 1 | 0 |
| Frontiers in Integrative Neuroscience | 25.8 | 1 | 0 |
| Surgical Neurology International | 25.8 | 1 | 0 |
| Frontiers in Computational Neuroscience | 25.8 | 1 | 0 |
| Journal of Clinical Imaging Science | 25.8 | 1 | 0 |
| Fluids and Barriers of the CNS | 25.8 | 1 | 0 |
| Mechthilde Wittmann | 25.8 | 1 | 0 |
| Department of Health and Aged Care | 25.8 | 1 | 0 |
| Department of Health and Ageing | 25.8 | 1 | 0 |
| Department of Health and Family Services | 25.8 | 1 | 0 |
| Suburban Hospital | 25.8 | 1 | 0 |
| Wikipedia:Lokal K | 25.8 | 1 | 0 |
| Gene Expression Omnibus | 25.8 | 1 | 0 |
| Margaret Goodell | 25.8 | 1 | 0 |
| American Journal of Cancer Research | 25.8 | 1 | 0 |
| NCBI Homo sapiens Annotation Release 106 | 25.8 | 1 | 0 |
| Julian Reichelt | 25.8 | 1 | 0 |
| OncoImmunology | 25.8 | 1 | 0 |
| NCBI Mus musculus Annotation Release 104 | 25.8 | 1 | 0 |
| Airlift Northwest | 25.8 | 1 | 0 |
| Category:Videos für Wikipedia-Artikel | 25.8 | 1 | 0 |
| Felix Gasbarra | 25.8 | 1 | 0 |
| Vollum Institute | 25.8 | 1 | 0 |
| International Archives of Medicine | 25.8 | 1 | 0 |
| Christiane Frohmann | 25.8 | 1 | 0 |
| Gerhard Trabert | 25.8 | 1 | 0 |
| Q19295255 | 25.8 | 1 | 0 |
| NCBI Acyrthosiphon pisum Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Ailuropoda melanoleuca Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Alligator mississippiensis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Anolis carolinensis Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Apaloderma vittatum Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Apis dorsata Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Apis mellifera Annotation Release 102 | 25.8 | 1 | 0 |
| NCBI Aptenodytes forsteri Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Astyanax mexicanus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Bactrocera cucurbitae Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Bactrocera dorsalis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Balaenoptera acutorostrata scammoni Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Balearica regulorum gibbericeps Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Beta vulgaris subsp. vulgaris Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Bison bison bison Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Bos taurus Annotation Release 104 | 25.8 | 1 | 0 |
| NCBI Brachypodium distachyon Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Brassica rapa Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Buceros rhinoceros silvestris Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Callithrix jacchus Annotation Release 102 | 25.8 | 1 | 0 |
| NCBI Callorhinchus milii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Calypte anna Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Camelina sativa Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Camelus bactrianus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Camelus dromedarius Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Camelus ferus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Camponotus floridanus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Caprimulgus carolinensis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Cariama cristata Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Chaetura pelagica Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Charadrius vociferus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Chelonia mydas Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Chlamydotis macqueenii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Chlorocebus sabaeus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Chrysemys picta Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Chrysochloris asiatica Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Ciona intestinalis Annotation Release 102 | 25.8 | 1 | 0 |
| NCBI Citrus sinensis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Colius striatus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Corvus brachyrhynchos Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Corvus cornix cornix Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Cricetulus griseus Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Cuculus canorus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Cucumis melo Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Cynoglossus semilaevis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Danio rerio Annotation Release 104 | 25.8 | 1 | 0 |
| NCBI Egretta garzetta Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Elaeis guineensis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Elephantulus edwardii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Eptesicus fuscus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Equus przewalskii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Erinaceus europaeus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Esox lucius Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Eucalyptus grandis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Eurypyga helias Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Felis catus Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Felis catus Annotation Release 102 | 25.8 | 1 | 0 |
| NCBI Fopius arisanus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Fukomys damarensis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Fulmarus glacialis Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Gavia stellata Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Glycine max Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Haliaeetus albicilla Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Haliaeetus leucocephalus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Harpegnathos saltator Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Larimichthys crocea Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Lepisosteus oculatus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Leptonychotes weddellii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Leptosomus discolor Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Lipotes vexillifer Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Loxodonta africana Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Malus domestica Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Manacus vitellinus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Meleagris gallopavo Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Merops nubicus Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Mesitornis unicolor Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Microplitis demolitor Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Monodelphis domestica Annotation Release 102 | 25.8 | 1 | 0 |
| NCBI Musa acuminata Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Musca domestica Annotation Release 101 | 25.8 | 1 | 0 |
| NCBI Myotis davidii Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Nannospalax galili Annotation Release 100 | 25.8 | 1 | 0 |
| NCBI Nasonia vitripennis Annotation Release 101 | 25.8 | 1 | 0 |
| Catherine, Princess of Wales | 17.2 | 0 | 1 |
| Systems Biology in Reproductive Medicine | 17.2 | 0 | 1 |
| Robert Edwards | 17.2 | 0 | 1 |
| Max Mosley | 17.2 | 0 | 1 |
| in vitro fertilization | 17.2 | 0 | 1 |
| ASA physical status classification system | 17.2 | 0 | 1 |
| Lemmy | 17.2 | 0 | 1 |
| reproductive medicine | 17.2 | 0 | 1 |
| Q457923 | 17.2 | 0 | 1 |
| Hank Green | 17.2 | 0 | 1 |
| egg donation | 17.2 | 0 | 1 |
| Tissue bank | 17.2 | 0 | 1 |
| Mark Souder | 17.2 | 0 | 1 |
| Jason Collins | 17.2 | 0 | 1 |
| theranostics | 17.2 | 0 | 1 |
| preoperative care | 17.2 | 0 | 1 |
| embryo cryopreservation | 17.2 | 0 | 1 |
| Creighton Model FertilityCare System | 17.2 | 0 | 1 |
| Andy Kershaw | 17.2 | 0 | 1 |
| A. A. Gill | 17.2 | 0 | 1 |
| Andrew Watson | 17.2 | 0 | 1 |
| Assisted zona hatching | 17.2 | 0 | 1 |
| Autologous endometrial coculture | 17.2 | 0 | 1 |
| Center for Reproductive Medicine | 17.2 | 0 | 1 |
| Endocrinology of reproduction | 17.2 | 0 | 1 |
| Ericsson method | 17.2 | 0 | 1 |
| fertility preservation | 17.2 | 0 | 1 |
| fertility tourism | 17.2 | 0 | 1 |
| diagnosis of lung cancer | 17.2 | 0 | 1 |
| Human Fertilisation and Embryology (Deceased Fathers) Act 2003 | 17.2 | 0 | 1 |
| Template:Assisted reproductive technology | 17.2 | 0 | 1 |
| ovarian tissue cryopreservation | 17.2 | 0 | 1 |
| poppy seed test | 17.2 | 0 | 1 |
| religious response to assisted reproductive technology | 17.2 | 0 | 1 |
| Reproductive endocrinology | 17.2 | 0 | 1 |
| reproductive surgery | 17.2 | 0 | 1 |
| semen collection | 17.2 | 0 | 1 |
| Slovenian fertility treatment referendum, 2001 | 17.2 | 0 | 1 |
| Special Program of Assisted Reproduction | 17.2 | 0 | 1 |
| third-party reproduction | 17.2 | 0 | 1 |
| veterinary oncology | 17.2 | 0 | 1 |
| Category:A-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Assisted reproductive technology | 17.2 | 0 | 1 |
| Category:B-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:C-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:FA-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:FL-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:GA-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:High-importance reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Low-importance reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Mid-importance reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Reproductive medicine articles by importance | 17.2 | 0 | 1 |
| Category:Reproductive medicine articles by quality | 17.2 | 0 | 1 |
| Category:Reproductive medicine task force | 17.2 | 0 | 1 |
| Category:Reproductive medicine task force articles | 17.2 | 0 | 1 |
| Category:NA-Class reproductive medicine pages | 17.2 | 0 | 1 |
| Category:NA-importance reproductive medicine pages | 17.2 | 0 | 1 |
| Category:Start-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Stub-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Top-importance reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Unassessed reproductive medicine articles | 17.2 | 0 | 1 |
| Category:Unknown-importance reproductive medicine articles | 17.2 | 0 | 1 |
| Category:List-Class reproductive medicine articles | 17.2 | 0 | 1 |
| Seminars in Reproductive Medicine | 17.2 | 0 | 1 |
| Molecular Human Reproduction | 17.2 | 0 | 1 |
| Journal of Reproductive Medicine | 17.2 | 0 | 1 |
| Obstetrics, Gynaecology and Reproductive Medicine | 17.2 | 0 | 1 |
| Anna Glasier | 17.2 | 0 | 1 |
| medical assistance to procreation in France | 17.2 | 0 | 1 |
| Partner-assisted reproduction | 17.2 | 0 | 1 |
| reproductive endocrinology and infertility | 17.2 | 0 | 1 |
| cystadenofibroma | 17.2 | 0 | 1 |